For example, a phase I clinical trial using CAR-NK cell therapy against anti-PDL1/MUC1, a glycoprotein known to be overexpressed in melanoma and promote metastasis, was shown to display a stable response in a majority of patients with a range of solid tumors [135,136]. Here, CD274 is linked to melanoma.